SMC's Changing Process
Companies at Meetings
From November 2014 the Scottish Medicines Consortium will invite sponsor companies to attend SMC meetings when one of their products is being considered (as a full submission or resubmission). Company representatives will be expected to respond to specific queries regarding the submission and be able to provide clarification on any outstanding issues. Further information can be found here.
SMC Meeting in Public
Scottish Medicine Consortium meetings are now open to the public to observe, in line with SMC's commitment to openness and transparency. Meeting in public will increase public awareness as to how evidence is assessed, interpreted and discussed, and the way that comments from Patient Interest Groups, pharmaceutical companies and clinicians inform how recommendations are made. Further information on observing an SMC meeting can be found here.
End of Life & Very Rare Conditions
The Scottish Medicines Consortium has been asked to apply more flexible approaches to the evaluation of medicines used at the end of life and for very rare conditions. The new processes include the option of a Patient and Clinican Engagement (PACE) group. This will give patient groups and clinicians a stronger voice in SMC decision making. In addition, the assessment process for ultra-orphan medicines will involve a broad decision-making framework. Read more about the PACE process here.
What we do
The remit of the Scottish Medicines Consortium (SMC) is to provide advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) across Scotland about the clinical and cost-effectiveness of all newly licensed medicines, all new formulations of existing medicines and new indications for established products (licensed from January 2002). Read more on what we do.
Guidelines for Industry
In this section you will find Guidelines for the Pharmaceutical Industry on our submission process.
Guidelines for Patient Groups
In this section you will find Guidelines for Patient Groups on our submission process.
Find out more
The SMC is a consortium of NHSScotland’s 14 Health Boards. It was established in 2001 to benefit patients by providing NHSScotland with a single source of advice about the value of each new medicine and the patients for whom it would be of most benefit.
Its advice also helps to facilitate the early introduction of beneficial treatments across Scotland.
A monthly Briefing Note is produced to provide a summary of SMC advice. It is written to help members of the media and other interested groups understand the work and advice of the Scottish Medicines Consortium.
The Scottish Medicines Consortium meets monthly on the first Tuesday of each month. Click here to view forthcoming submissions that have been scheduled for assessment over the coming 2/3 months.